Source: Annual Congress 2004 - Exploring new basic aspects of treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Nejman, H. Grubek-Jaworska, J. Glapinski, G. Hoser, R. Chazan (Warsaw, Poland). Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model. Eur Respir J 2004; 24: Suppl. 48, 865

Member's Comments

No comment yet.

Related content which might interest you: A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Effect of thromboxane A2(TXA2) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 The selective PDE4-inhibitor AWD 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD: comparison with steroids Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001 First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001